Rising Prevalence of Various Diseases to Create Scope for the North American Nanomedicine Market Growth

The North American Nanomedicine market is anticipated to grow significantly at a CAGR of 11.0% over the forecast period (2021-2027). The key aspect that drives the growth of the North American nanomedicine market is the rising prevalence of various diseases such as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others, and the need to curb the demand for the treatment of such diseases. According to WHO, around 17.9 million fatalities occur each year due to these heart diseases, which is estimated to be around 31% of global fatalities. 

Browse the full report description North American Nanomedicines Market Size, Share & Trends Analysis Report By Indication Type (Cardiovascular Diseases, Neurological Diseases, Infectious Diseases, Oncological Diseases, Orthopedic Diseases, and Other Diseases (Urological Disease, Ophthalmic Diseases)), and by Application (Drug Delivery, Active Implants, Vaccines, Diagnostic Imaging, Biomaterials, Regenerative Medicines, and Other Applications (Tissue Regeneration)) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/north-american-nanomedicines-market

Amongst these fatalities, around 7.4 million had CHD and approx. 6.7 million fatalities occurred due to a stroke. By 2030, it has been projected that CVDs will be responsible for approx. 23.6 million mortalities across the globe. An unhealthy diet, excessive consumption of alcohol and tobacco, and physical inactivity are the major factors that are giving rise to the incidence and prevalence rates of heart diseases. The rapidly increasing prevalence of heart diseases also leads to an alarming number of fatalities around the globe. Hence, this generates the need for advanced treatment options such as nanomedicines, this, in turn, increases the growth opportunities for the market over the forecast period.

Market Coverage

• Market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- By Indication Type and By Applications
• Region Covered- North America
• Competitive Landscape- 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Nanomedicine Market – Segmentation

By Indication Type

• Cardiovascular Diseases
• Neurological Diseases
• Infectious Diseases
• Oncological Diseases
• Orthopedic Diseases
• Other Diseases (Urological Disease, Ophthalmic Diseases)

By Application

• Drug Delivery
• Active Implants
• Vaccines
• Diagnostic Imaging
• Biomaterials
• Regenerative Medicines
• Other Applications (Tissue Regeneration)

North America Nanomedicine Market – Countries Covered

North America  

• The US
• Canada